This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Enterome | |
|---|---|
| Name | Enterome |
| Type | Private |
| Industry | Biotechnology |
| Founded | 2012 |
| Headquarters | Paris, France |
| Key people | Pierre Belichard (CEO), Gérard Eberl (Co-founder) |
| Products | Microbiome-derived therapeutics, diagnostics |
Enterome is a French biotechnology company focused on microbiome-derived therapeutics and diagnostics. Founded in 2012, the company pursued programs in oncology, immuno-oncology, and inflammatory bowel disease while engaging with academic institutions and pharmaceutical partners. Its work intersected with translational research, venture capital, and global clinical development.
Enterome was established amid rising interest in microbiome research that involved figures and institutions such as James P. Allison, Tasuku Honjo, Harvard University, Massachusetts Institute of Technology, Stanford University, University of Oxford, and Institut Pasteur. Early collaborations drew on knowledge from microbial ecology studies associated with Carl Woese and sequencing projects like the Human Microbiome Project and the Earth Microbiome Project. The company expanded its pipeline during a period when biotechnology firms including Moderna, Illumina, Gilead Sciences, Roche, Novartis, and Pfizer were increasing investments in microbiome and immunotherapy approaches. Enterome’s trajectory was shaped by milestones in genomics and immunology such as the work recognized by the Nobel Prize in Physiology or Medicine and by regulatory decisions from agencies like the European Medicines Agency and the Food and Drug Administration.
The company’s leadership included founders and executives with academic and industry backgrounds who engaged with institutions like Inserm, CEA, CNRS, Collège de France, and universities across Europe and the United States. Board members and advisors often had affiliations with organizations such as Goldman Sachs, Sequoia Capital, Société Générale, Bain Capital, BlackRock, Bertelsmann, and SoftBank. Enterome worked with law firms and advisory groups that had history representing clients in transactions involving GlaxoSmithKline, AstraZeneca, Sanofi, and Bristol-Myers Squibb. Strategic hires frequently drew talent from companies like Sanofi, Novartis, Roche, Merck & Co., and academic spin-outs from École Polytechnique and Sorbonne University.
Research programs leveraged computational and experimental platforms influenced by advances at Broad Institute, Wellcome Trust Sanger Institute, European Molecular Biology Laboratory, Cold Spring Harbor Laboratory, and Riken. Enterome’s R&D integrated metagenomics, metabolomics, and immunoprofiling methods pioneered alongside teams at Dana-Farber Cancer Institute, Mayo Clinic, Johns Hopkins University, Karolinska Institutet, Max Planck Society, and Weizmann Institute of Science. Collaborations and publications often referenced methodological frameworks and datasets from The Cancer Genome Atlas, ENCODE Project, Genome Aggregation Database, and clinical biomarker efforts coordinated with National Institutes of Health programs. The company advanced discovery using CROs and partners such as Charles River Laboratories, IQVIA, PRA Health Sciences, and Covance.
Enterome developed microbiome-derived therapeutic candidates and diagnostic platforms intended to modulate host-microbiota interactions, using approaches related to technologies commercialized by entities like Ginkgo Bioworks, Synlogic, Seres Therapeutics, Ferring Pharmaceuticals, and SecondGenome. Their platforms combined high-throughput sequencing enabled by Illumina NovaSeq instruments, mass spectrometry used in workflows from Thermo Fisher Scientific, and bioinformatics tools inspired by software from EMBL-EBI, NCBI, Google DeepMind, and Microsoft Research. The product portfolio targeted indications prioritized by major health organizations such as World Health Organization and intersected with therapeutic areas addressed by Amgen, Regeneron Pharmaceuticals, Bayer, and Takeda Pharmaceutical Company Limited.
Clinical development involved multi-center studies coordinated with hospitals and networks including European Society for Medical Oncology, American Society of Clinical Oncology, Mayo Clinic, Cleveland Clinic, Hospital for Sick Children, and university hospitals affiliated with Université Paris Cité. Enterome partnered or engaged in licensing discussions with pharmaceutical companies and alliances comparable to deals made by Bristol-Myers Squibb and Eli Lilly and Company. Trials adhered to guidance from regulatory bodies like the European Commission and national health agencies and referenced outcome measures and endpoints used in studies supported by foundations such as the Bill & Melinda Gates Foundation, Wellcome Trust, and Chan Zuckerberg Initiative.
As with other ventures in the microbiome sector, Enterome faced scientific and commercial scrutiny similar to debates surrounding Seres Therapeutics, Ferring Pharmaceuticals, and other biotech firms regarding reproducibility, heterogeneity of microbiome data, and translational gaps highlighted by critics from Nature, Science (journal), The Lancet, and commentators associated with The New York Times and Financial Times. Ethical and regulatory discussions involved frameworks from bodies like European Commission, Council of Europe, and bioethics panels connected to UNESCO and the Nuffield Council on Bioethics. Commercial critiques echoed concerns raised in high-profile cases involving Theranos, investor reactions akin to those faced by WeWork, and litigation patterns observed with biotechnology disputes in courts such as United States District Court for the District of Massachusetts and European patent tribunals.
Funding rounds and financial activity engaged venture capital, strategic pharma partnerships, and public-private funding mechanisms similar to transactions involving Seventure Partners, Sofinnova Partners, Bpifrance, European Investment Bank, Temasek, and European Innovation Council. Investors and stakeholders included institutional backers comparable to Goldman Sachs, Caisse des Dépôts, and family offices that have supported biotech portfolios alongside firms like Index Ventures and Accel Partners. Financial reporting and capital strategy referenced market dynamics observed in public offerings and M&A deals executed by Moderna, Gilead Sciences, Roche, and cross-border transactions mediated by advisers from Deloitte, PwC, and Ernst & Young.
Category:Biotechnology companies